CL2020001073A1 - Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. - Google Patents

Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.

Info

Publication number
CL2020001073A1
CL2020001073A1 CL2020001073A CL2020001073A CL2020001073A1 CL 2020001073 A1 CL2020001073 A1 CL 2020001073A1 CL 2020001073 A CL2020001073 A CL 2020001073A CL 2020001073 A CL2020001073 A CL 2020001073A CL 2020001073 A1 CL2020001073 A1 CL 2020001073A1
Authority
CL
Chile
Prior art keywords
contain
pharmaceutical compositions
preparation process
macrocyclic derivatives
new macrocyclic
Prior art date
Application number
CL2020001073A
Other languages
English (en)
Inventor
I-Jen Chen
Jérôme-Benoît Starck
Didier Durand
Tiran Arnaud Le
Jean-Claude Ortuno
Miklós Nyerges
Melinda Ligeti
Imre Fejes
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CL2020001073A1 publication Critical patent/CL2020001073A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C07F9/65335—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuesto de fórmula (I): en la que A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y y G son tales como se han definido en la descripción, y su utilización en la fabricación de medicamentos
CL2020001073A 2017-10-25 2020-04-21 Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. CL2020001073A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1760078A FR3072679B1 (fr) 2017-10-25 2017-10-25 Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CL2020001073A1 true CL2020001073A1 (es) 2020-12-04

Family

ID=61599283

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001073A CL2020001073A1 (es) 2017-10-25 2020-04-21 Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.

Country Status (25)

Country Link
US (1) US11833162B2 (es)
EP (1) EP3700911B1 (es)
JP (1) JP7253543B2 (es)
KR (1) KR102645096B1 (es)
CN (1) CN111511750B (es)
AR (1) AR113789A1 (es)
AU (1) AU2018355709B2 (es)
CA (1) CA3080116C (es)
CL (1) CL2020001073A1 (es)
CR (1) CR20200169A (es)
EA (1) EA202090978A1 (es)
EC (1) ECSP20023535A (es)
ES (1) ES2963996T3 (es)
FR (1) FR3072679B1 (es)
IL (1) IL274141A (es)
JO (1) JOP20200089A1 (es)
LT (1) LT3700911T (es)
MA (1) MA50450B1 (es)
MX (1) MX2020004345A (es)
NI (1) NI202000028A (es)
PE (1) PE20201498A1 (es)
PH (1) PH12020550448A1 (es)
SG (1) SG11202003550VA (es)
TW (1) TWI685498B (es)
WO (1) WO2019081559A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110256245A (zh) * 2019-06-06 2019-09-20 常州合全药业有限公司 一种4-氯-2-溴苯甲酸叔丁酯的合成方法
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
CN116997544A (zh) * 2021-03-24 2023-11-03 法国施维雅药厂 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用
KR102589629B1 (ko) 2021-10-06 2023-10-13 한국생명공학연구원 파우시박터 아쿠아틸 유래 신규 화합물 및 이의 용도
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
JPWO2024214321A1 (es) * 2023-04-10 2024-10-17
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2014022752A1 (en) * 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
FR3008979B1 (fr) 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1

Also Published As

Publication number Publication date
MX2020004345A (es) 2020-10-14
KR20200077541A (ko) 2020-06-30
US11833162B2 (en) 2023-12-05
WO2019081559A1 (fr) 2019-05-02
RU2020116154A3 (es) 2022-03-11
US20200253993A1 (en) 2020-08-13
JP2021500370A (ja) 2021-01-07
IL274141A (en) 2020-06-30
TWI685498B (zh) 2020-02-21
CN111511750B (zh) 2023-06-13
EP3700911B1 (fr) 2023-09-06
EA202090978A1 (ru) 2020-09-07
ECSP20023535A (es) 2020-05-29
AU2018355709B2 (en) 2023-02-23
NI202000028A (es) 2020-10-06
TW201922754A (zh) 2019-06-16
MA50450B1 (fr) 2023-10-31
LT3700911T (lt) 2023-10-10
CA3080116A1 (fr) 2019-05-02
CN111511750A (zh) 2020-08-07
CR20200169A (es) 2020-06-14
FR3072679A1 (fr) 2019-04-26
MA50450A (fr) 2020-09-02
RU2020116154A (ru) 2021-11-25
PE20201498A1 (es) 2020-12-29
JOP20200089A1 (ar) 2020-05-03
SG11202003550VA (en) 2020-05-28
AR113789A1 (es) 2020-06-10
AU2018355709A1 (en) 2020-05-07
EP3700911A1 (fr) 2020-09-02
ES2963996T3 (es) 2024-04-03
CA3080116C (fr) 2023-01-10
PH12020550448A1 (en) 2021-04-26
BR112020007924A2 (pt) 2020-10-20
KR102645096B1 (ko) 2024-03-06
FR3072679B1 (fr) 2020-10-30
JP7253543B2 (ja) 2023-04-06

Similar Documents

Publication Publication Date Title
CL2020001073A1 (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
ECSP14008757A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2017016995A (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX374443B (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP14008606A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20160031A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen